OncoMatch/Clinical Trials/NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
Is NCT07645222 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies multiple treatments including HS-20122+Aumolertinib and HS-20122+Adbrelimab for lung cancer.
Treatment: HS-20122+Aumolertinib · HS-20122+Adbrelimab · HS-20122+Adbrelimab+Platinum-based Chemo — This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic glucocorticoids
History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
Lab requirements
Blood counts
Kidney function
Liver function
Appropriate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07645222 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic glucocorticoids disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages